BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Meuwissen SG, Craanen ME, Kuipers EJ. Gastric mucosal morphological consequences of acid suppression: a balanced view.Best Pract Res Clin Gastroenterol. 2001;15:497-510. [PMID: 11403542 DOI: 10.1053/bega.2001.0189] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
Number Citing Articles
1 Li ZP, Liu JX, Lu LL, Wang LL, Xu L, Guo ZH, Dong QJ. Overgrowth of Lactobacillus in gastric cancer. World J Gastrointest Oncol 2021; 13(9): 1099-1108 [PMID: 34616515 DOI: 10.4251/wjgo.v13.i9.1099] [Reference Citation Analysis]
2 Ardill JE. Circulating markers for endocrine tumours of the gastroenteropancreatic tract. Ann Clin Biochem. 2008;45:539-559. [PMID: 18941127 DOI: 10.1258/acb.2008.008039] [Cited by in Crossref: 38] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
3 Graham DY, Chan FK. NSAIDs, Risks, and Gastroprotective Strategies: Current Status and Future. Gastroenterology 2008;134:1240-6. [DOI: 10.1053/j.gastro.2008.02.007] [Cited by in Crossref: 41] [Cited by in F6Publishing: 29] [Article Influence: 2.9] [Reference Citation Analysis]
4 Jensen RT. Consequences of long-term proton pump blockade: insights from studies of patients with gastrinomas. Basic Clin Pharmacol Toxicol. 2006;98:4-19. [PMID: 16433886 DOI: 10.1111/j.1742-7843.2006.pto_378.x] [Cited by in Crossref: 90] [Cited by in F6Publishing: 76] [Article Influence: 5.6] [Reference Citation Analysis]
5 Del Piano M, Pagliarulo M, Tari R, Carmagnola S, Balzarini M, Lorenzini P, Pane M. Correlation between chronic treatment with proton pump inhibitors and bacterial overgrowth in the stomach: any possible beneficial role for selected lactobacilli? J Clin Gastroenterol. 2014;48 Suppl 1:S40-S46. [PMID: 25291126 DOI: 10.1097/mcg.0000000000000256] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
6 Bytzer P, Blum AL. Personal view: rationale and proposed algorithms for symptom-based proton pump inhibitor therapy for gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2004;20:389-398. [PMID: 15298632 DOI: 10.1111/j.1365-2036.2004.02093.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
7 Zabaleta J, Camargo MC, Piazuelo MB, Fontham E, Schneider BG, Sicinschi LA, Ferrante W, Balart L, Correa P, Ochoa AC. Association of interleukin-1beta gene polymorphisms with precancerous gastric lesions in African Americans and Caucasians. Am J Gastroenterol. 2006;101:163-171. [PMID: 16405550 DOI: 10.1111/j.1572-0241.2006.00387.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 2.4] [Reference Citation Analysis]
8 Bergman MP, Klinkenberg-Knol EC, Faller G, Aar A, Lakhai W, Vandenbroucke-Grauls CM, Kuipers EJ, Appelmelk BJ. Long-term acid suppression by omeprazole in gastro-oesophageal reflux disease patients does not lead to anti-gastric autoantibody production. Aliment Pharmacol Ther 2005;21:977-83. [PMID: 15813833 DOI: 10.1111/j.1365-2036.2005.02386.x] [Reference Citation Analysis]
9 van Marrewijk CJ, van Oijen MG, Paloheimo LI, Fransen GA, Mujakovic S, Muris JW, Numans ME, De Wit NJ, Grobbee DE, Knottnerus JA, Laheij RJ, Jansen JB. Influence of gastric mucosal status on success of stepwise acid suppressive therapy for dyspepsia. Aliment Pharmacol Ther 2009;30:82-9. [PMID: 19309389 DOI: 10.1111/j.1365-2036.2009.04001.x] [Reference Citation Analysis]
10 Gibbons TE, Gold BD. The use of proton pump inhibitors in children: a comprehensive review. Paediatr Drugs 2003;5:25-40. [PMID: 12513104 DOI: 10.2165/00128072-200305010-00003] [Cited by in Crossref: 69] [Cited by in F6Publishing: 46] [Article Influence: 3.6] [Reference Citation Analysis]
11 Williams C, McColl KE. Review article: proton pump inhibitors and bacterial overgrowth. Aliment Pharmacol Ther. 2006;23:3-10. [PMID: 16393275 DOI: 10.1111/j.1365-2036.2006.02707.x] [Cited by in Crossref: 161] [Cited by in F6Publishing: 125] [Article Influence: 10.1] [Reference Citation Analysis]
12 Eurich DT, Sadowski CA, Simpson SH, Marrie TJ, Majumdar SR. Recurrent community-acquired pneumonia in patients starting acid-suppressing drugs. Am J Med. 2010;123:47-53. [PMID: 20102991 DOI: 10.1016/j.amjmed.2009.05.032] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 3.8] [Reference Citation Analysis]
13 Menegassi VDS, Czeczko LEA, Czeczko LSG, Ioshii SO, Pisani JC, Ramos Junior O. Prevalência de alterações proliferativas gástricas em pacientes com uso crônico de inibidores de bomba de prótons. ABCD, arq bras cir dig 2010;23:145-9. [DOI: 10.1590/s0102-67202010000300003] [Cited by in Crossref: 6] [Article Influence: 0.5] [Reference Citation Analysis]
14 Goldstein NS. Chronic inactive gastritis and coccoid Helicobacter pylori in patients treated for gastroesophageal reflux disease or with H pylori eradication therapy. Am J Clin Pathol 2002;118:719-26. [PMID: 12428792 DOI: 10.1309/LJ4D-E2LX-7UMR-YMTH] [Cited by in Crossref: 32] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
15 Del Piano M, Anderloni A, Balzarini M, Ballarè M, Carmagnola S, Montino F, Orsello M, Pagliarulo M, Tari R, Soattini L, Sforza F, Mogna L, Mogna G. The Innovative Potential of Lactobacillus rhamnosus LR06, Lactobacillus pentosus LPS01, Lactobacillus plantarum LP01, and Lactobacillus delbrueckii Subsp. delbrueckii LDD01 to Restore the “Gastric Barrier Effect” in Patients Chronically Treated With PPI: A Pilot Study. Journal of Clinical Gastroenterology 2012;46:S18-26. [DOI: 10.1097/mcg.0b013e318267b55d] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
16 Waldum H, Fossmark R. Gastritis, Gastric Polyps and Gastric Cancer. Int J Mol Sci 2021;22:6548. [PMID: 34207192 DOI: 10.3390/ijms22126548] [Reference Citation Analysis]